Hancock Whitney Corp reduced its Zimmer Biomet Holdings stock position by 9.7% in Q1 2021.

Hancock Whitney Corp, an institutional investor, reduced its Zimmer Biomet Holdings stock position by 9.7% in Q1 2021. Zimmer Biomet reported a $1.94 EPS for the latest quarter, exceeding the consensus estimate by $0.07. The company's current share price is $109.04, with a predicted 8.1 EPS for the current fiscal year. Zimmer Biomet operates as a medical technology company in orthopedic reconstructive products and other medical technologies. Other institutional investors have also adjusted their holdings in ZBH, with several increasing or maintaining their stakes in Q1.

August 02, 2024
5 Articles